Advanced Biotherapy Inc. Completes Second Clinical Study in Rheumatoid Arthritis Patients: Further Support Provided for Efficacy of Company's Treatment Protocol.Business Editors & Health/Medical Writers SAN DIEGO--(BW HealthWire)--Oct. 3, 2000 Advanced Biotherapy biotherapy /bio·ther·a·py/ (-ther´ah-pe) biological therapy. bi·o·ther·a·py n. Treatment of disease with biologicals, such as vaccines. Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ADVB ADVB Associação dos Dirigentes de Vendas e Marketing do Brasil ) reported today the results of a 30-patient randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. , double-blind, placebo-controlled clinical trial evaluating the efficacy of its proprietary Anti-Interferon gamma drug (Anti-IFNg) in Rheumatoid Arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. patients. The Anti-IFNg-treated patients showed statistically significant improvements at both seven and 28 days post-treatment relative to placebo-treated patients in a variety of clinically relevant endpoints. The clinical trial assessed the efficacy of a five-day intramuscular-administered (twice daily) treatment course of Anti-IFNg with that of placebo and Anti-Tumor Necrosis Factor alpha (Anti-TNFa). The patients were clinically assessed for seven days on a daily basis and then weekly up to 28 days. The clinical parameters included numbers of swollen and painful joints, duration of morning stiffness, grip strength, pain and fatigue and both patient and physician global assessment. Both the Anti-Cytokine groups showed significant improvements at seven and 28 days with the Anti-IFNg group demonstrating the more robust effect at day 28. Commenting on the results, Dr. Paul J. Marangos, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ADVB, stated, "We are pleased that this second trial supports the results of our earlier published study (INT. J. Immunotherapy XIV (1) 23-32, 1998) in Rheumatoid Arthritis patients, and are excited about developing the Anti-IFNg treatment strategy into a marketable product." ADVB is developing proprietary treatments for a range of autoimmune diseases, including Rheumatoid Arthritis, Multiple Sclerosis, Type I Diabetes Type I diabetes Also called juvenile diabetes. Type I diabetes typically begins early in life. Affected individuals have a primary insulin deficiency and must take insulin injections. Mentioned in: Diabetic Ketoacidosis and AIDS. The company's drugs neutralize immunomodulators called Cytokines Cytokines Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors. , which have now been shown to be linked to these diseases. Statements made in this release, other than statements of historical fact, are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the results of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of the company's patent portfolio. See the company's public filings with the Securities and Exchange Commission for information about risks that may affect the company. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion